19,23,24,25,26,27-Hexanor-1alpha-hydroxyvitamin D3

• US 20070066566A1
• Filed: 09/19/2006
• Published: 03/22/2007
• Est. Priority Date: 09/22/2005
• Status: Abandoned Application

• Current Assignee: Wisconsin Alumni Research Foundation (University of Wisconsin System)
• Original Assignee: Wisconsin Alumni Research Foundation (University of Wisconsin System)
• Inventors: Plum, Lori, Clagett-Dame, Margaret, Grzywacz, Pawel, DeLuca, Hector
• Application Number:
  US11/523,750
• Publication Number:
  US 20070066566A1
• Time in Patent Office: Days
• US Class Current: 514/63
• CPC Class Codes: A61P 1/04 for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• CPC Class Codes: A61P 11/06 Antiasthmatics
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 17/02 for treating wounds, ulcers, burns, scars, keloids, or the like
• CPC Class Codes: A61P 17/04 Antipruritics
• CPC Class Codes: A61P 17/06 Antipsoriatics
• CPC Class Codes: A61P 17/16 Emollients or protectives, e.g. against radiation
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 19/08 for bone diseases, e.g. rachitism, Paget's disease
• CPC Class Codes: A61P 19/10 for osteoporosis
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 3/02 Nutrients, e.g. vitamins, minerals
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 3/14 for calcium homeostasis vitamin D A61P3/02; parathyroid hormones A61P5/18; calcitonin A61P5/22; osteoporosis A61P19/10; bone metastasis A61P35/04
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 35/02 specific for leukemia
• CPC Class Codes: A61P 37/06 Immunosuppressants, e.g. drugs for graft rejection
• CPC Class Codes: A61P 5/18 of the parathyroid hormones
• CPC Class Codes: C07C 401/00 Irradiation products of cholesterol or its derivatives; Vitamin D derivatives, 9,10-seco cyclopenta[a]phenanthrene or analogues obtained by chemical preparation without irradiation
• CPC Class Codes: Y02P 20/55 : Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Abstract

A compound or composition is provided that comprises a compound of formula 1A,
where, X¹ and X² are independently selected from H or hydroxy-protecting groups. Also provided are compounds that form the compound of formula 1A after they are administered to a subject.

Claims

1. A compound or composition comprising a compound of formula 1A,

wherein,

X¹ and X² are independently selected from H or hydroxy-protecting groups, or a compound that forms the compound of formula IA in a subject after administration.

2. The compound or composition of claim 1, wherein X¹ and X² are both hydroxy protecting groups.

3. The compound or composition of claim 2, wherein X¹ and X² are both t-butyldimethylsilyl groups.

4. The compound or composition of claim 1, wherein X¹ and X² are both H such that the compound has the formula 1B

5. A pharmaceutical formulation, comprising:

the compound of claim 1 and a pharmaceutically acceptable carrier.

6. The pharmaceutical formulation of claim 5, wherein the amount of the compound in the pharmaceutical formulation ranges from about 0.01 μ

g to about 1 mg per gram of the pharmaceutical formulation.

7. The pharmaceutical formulation of claim 6, wherein the amount of the compound in the pharmaceutical formulation ranges from about 0.1 μ

g to about 500 μ

g per gram of the pharmaceutical formulation.

8. The pharmaceutical formulation of claim 5, wherein X¹ and X² are both H such that the compound has the formula 1B

9. A method of treating a subject suffering from a biological disorder, comprising administering an effective amount of the compound or composition of claim 1 or a pharmaceutical formulation comprising the compound of claim 1 and a pharmaceutically acceptable carrier to the subject.

10. The method of claim 9, wherein the compound, the composition, or the pharmaceutical formulation is administered orally, parenterally, rectally, transdermally, or topically to the subject.

11. The method of claim 9, wherein the compound, the composition, or the pharmaceutical formulation is administered by delivering the compound, the composition, or the pharmaceutical formulation in an aerosol.

12. The method of claim 9, wherein the biological condition is selected from psoriasis;

leukemia;

colon cancer;

breast cancer;

prostate cancer;

multiple sclerosis;

lupus;

diabetes mellitus;

host versus graft reaction;

rejection of organ transplants;

an inflammatory disease selected from rheumatoid arthritis, asthma, eczema, or inflammatory bowel diseases;

a skin condition selected from wrinkles, lack of adequate skin firmness, lack of adequate dermal hydration, or insufficient sebum secretion;

or secondary hyperparathyroidism.

13. The method of claim 9, wherein the biological condition is a skin condition.

14. The method of claim 12, wherein the skin condition is selected from wrinkles, lack of adequate skin firmness, lack of adequate dermal hydration, eczema, psoriasis, or insufficient sebum secretion.

15. The method of claim 9, wherein X¹ and X² are both H such that the compound has the formula 1B